Sleep Disorders

>

Latest News

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor
Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

January 17th 2025

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity
FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

December 20th 2024

Role of Sleep in Dementia and Associated Comorbidities: Daily Dose / image credit: ©New Africa/AdobeStock
Role of Sleep in Dementia and Associated Comorbidities: Daily Dose

December 13th 2024

New Review Highlights Need to Address Sleep Disturbances in Patients with Dementia / Image credit: ©netrun78/AdobeStock
New Review Highlights Need to Address Sleep Disturbances in Patients with Dementia

December 2nd 2024

Sex-Specific Dementia Risk in Older Adults with OSA: Daily Dose / image credit: ©New Africa/AdobeStock
Sex-Specific Dementia Risk in Older Adults with OSA: Daily Dose

November 26th 2024

Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.